|
V.SBM
|
If those business milestones are indeed achieved in the next two months as...
|
|
V.SBM
|
I was thinking about the spot reducer usage. Although its not as powerful as...
|
|
V.SBM
|
Well said iscfa, anothet overlooked point is the BP Co. partner created the...
|
|
V.SBM
|
Big Pharma paid for trial and may have proprietor rights to data, with a...
|
|
V.SBM
|
The time between the last announcements of trial .2% results and confirmation...
|
|
V.SBM
|
To be fair, market cap increase was significantly buoyed by increasing shares...
|
|
V.KNE
|
Something is going on here. I can only guess that 3rd party veterinarian...
|
|
V.SBM
|
The 15 ml size tube for spot correction only is the real surprise. The...
|
|
V.SBM
|
The photo of the spotless Dalmation in the mirror is nice marketing..
|
|
V.SBM
|
Initial sales numbers post launch may be used as a peer group reinforcement...
|
|
V.SBM
|
R + F should target their customers that previously ordered HydroQ with a...
|
|
V.SBM
|
& placing buy orders may help retain shares and slow the bleeding...
|
|
V.SBM
|
Raising awareness could include those that read this to order their own tube...
|
|
V.SBM
|
That Price Target at that time turns out to be accurate, taking into account...
|
|
V.SBM
|
Could be a SGLT2/Metformin or SGLT2/DPP4i combination tablet
|
|
V.SBM
|
When at least 3 near term runnups are expected and a new product, promoted by...
|
|
V.SBM
|
That has always been the trend it seems, sell on rumour, buy back 3 days post...
|
|
V.SBM
|
That has always been the trend it seems, sell on rumour, buy back 3 days post...
|
|
V.SBM
|
In the NR, Howie said he was going to do everything exactly the same for all...
|
|
V.KNE
|
Volumes spiked recently. I saw this pattern back with Kane was at .08...
|